Multivariate analyses
. | Analysis after induction therapy . | . | . | . | Analysis after consolidation therapy . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | RFS . | . | OS . | . | RFS . | . | OS . | . | ||||||
. | P . | RR (95% Cl) . | P . | RR (95% Cl) . | P . | RR (95% Cl) . | P . | RR (95% Cl) . | ||||||
| LD | .006 | 0.348 (0.163-0.742) | n.a. | — | .006 | 0.397 (0.205-0.767) | n.a.* | n.a. | ||||||
| Unfavorable karyotype | .0001 | 7.178 (2.638-19.528) | n.s. | — | .015 | 4.370 (1.327-14.394) | n.a. | — | ||||||
| WBC count | n.s. | — | .064 | 1.01 (1.00-1.02)† | n.a. | — | n.a. | — | ||||||
| Percentage of BM blasts at diagnosis | n.a. | — | n.a. | — | n.s. | — | n.a. | — | ||||||
. | Analysis after induction therapy . | . | . | . | Analysis after consolidation therapy . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | RFS . | . | OS . | . | RFS . | . | OS . | . | ||||||
. | P . | RR (95% Cl) . | P . | RR (95% Cl) . | P . | RR (95% Cl) . | P . | RR (95% Cl) . | ||||||
| LD | .006 | 0.348 (0.163-0.742) | n.a. | — | .006 | 0.397 (0.205-0.767) | n.a.* | n.a. | ||||||
| Unfavorable karyotype | .0001 | 7.178 (2.638-19.528) | n.s. | — | .015 | 4.370 (1.327-14.394) | n.a. | — | ||||||
| WBC count | n.s. | — | .064 | 1.01 (1.00-1.02)† | n.a. | — | n.a. | — | ||||||
| Percentage of BM blasts at diagnosis | n.a. | — | n.a. | — | n.s. | — | n.a. | — | ||||||